Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity

Khaleel I. Al-Obaidy, John N. Eble, Mehdi Nassiri, Liang Cheng, Mohammad K. Eldomery, Sean R. Williamson, Wael A. Sakr, Nilesh Gupta, Oudai Hassan, Muhammad T. Idrees, David J. Grignon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We recently proposed that an epithelial renal tumor “papillary renal neoplasm with reverse polarity” represents a distinct entity. It constituted 4% of previously diagnosed papillary renal cell carcinoma at the participating institutions. Histologically, it is characterized by papillary or tubulopapillary architecture covered by a single layer of eosinophilic cells with finely granular cytoplasm and apically located nuclei. It is characteristically positive for GATA3 and L1CAM and lack vimentin and, to a lesser extent, α-methylacyl-CoA-racemase (AMACR/p504s) immunostaining. To investigate the molecular pathogenesis of these tumors, we performed targeted next-generation sequencing on ten previously reported papillary renal neoplasms with reverse polarity, followed by a targeted polymerase chain reaction analysis for KRAS mutations in a control series of 30 type 1 and 2 papillary renal cell carcinomas. KRAS missense mutations were identified in eight of ten papillary renal neoplasms with reverse polarity. These mutations were clustered in exon 2—codon 12: c.35 G > T (n = 6) or c.34 G > C (n = 2) resulting in p.Gly12Val and p.Gly12Arg alterations, respectively. One of the wild-type tumors had BRAF c.1798_1799delGTinsAG (p.Val600Arg) mutation. No KRAS mutations were identified in any of the 30 control tumors. In summary, this study supports our proposal that papillary renal neoplasm with reverse polarity is an entity distinct from papillary renal cell carcinoma and the only renal cell neoplasm to consistently harbor KRAS mutations.

Original languageEnglish (US)
JournalModern Pathology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Kidney Neoplasms
Mutation
Renal Cell Carcinoma
Neoplasms
Neural Cell Adhesion Molecule L1
Racemases and Epimerases
Vimentin
Missense Mutation
Coenzyme A
Exons
Cytoplasm
Kidney
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Al-Obaidy, K. I., Eble, J. N., Nassiri, M., Cheng, L., Eldomery, M. K., Williamson, S. R., ... Grignon, D. J. (Accepted/In press). Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Modern Pathology. https://doi.org/10.1038/s41379-019-0362-1

Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. / Al-Obaidy, Khaleel I.; Eble, John N.; Nassiri, Mehdi; Cheng, Liang; Eldomery, Mohammad K.; Williamson, Sean R.; Sakr, Wael A.; Gupta, Nilesh; Hassan, Oudai; Idrees, Muhammad T.; Grignon, David J.

In: Modern Pathology, 01.01.2019.

Research output: Contribution to journalArticle

Al-Obaidy, KI, Eble, JN, Nassiri, M, Cheng, L, Eldomery, MK, Williamson, SR, Sakr, WA, Gupta, N, Hassan, O, Idrees, MT & Grignon, DJ 2019, 'Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity', Modern Pathology. https://doi.org/10.1038/s41379-019-0362-1
Al-Obaidy, Khaleel I. ; Eble, John N. ; Nassiri, Mehdi ; Cheng, Liang ; Eldomery, Mohammad K. ; Williamson, Sean R. ; Sakr, Wael A. ; Gupta, Nilesh ; Hassan, Oudai ; Idrees, Muhammad T. ; Grignon, David J. / Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. In: Modern Pathology. 2019.
@article{179e2de1352548ffaae446b0f534b02f,
title = "Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity",
abstract = "We recently proposed that an epithelial renal tumor “papillary renal neoplasm with reverse polarity” represents a distinct entity. It constituted 4{\%} of previously diagnosed papillary renal cell carcinoma at the participating institutions. Histologically, it is characterized by papillary or tubulopapillary architecture covered by a single layer of eosinophilic cells with finely granular cytoplasm and apically located nuclei. It is characteristically positive for GATA3 and L1CAM and lack vimentin and, to a lesser extent, α-methylacyl-CoA-racemase (AMACR/p504s) immunostaining. To investigate the molecular pathogenesis of these tumors, we performed targeted next-generation sequencing on ten previously reported papillary renal neoplasms with reverse polarity, followed by a targeted polymerase chain reaction analysis for KRAS mutations in a control series of 30 type 1 and 2 papillary renal cell carcinomas. KRAS missense mutations were identified in eight of ten papillary renal neoplasms with reverse polarity. These mutations were clustered in exon 2—codon 12: c.35 G > T (n = 6) or c.34 G > C (n = 2) resulting in p.Gly12Val and p.Gly12Arg alterations, respectively. One of the wild-type tumors had BRAF c.1798_1799delGTinsAG (p.Val600Arg) mutation. No KRAS mutations were identified in any of the 30 control tumors. In summary, this study supports our proposal that papillary renal neoplasm with reverse polarity is an entity distinct from papillary renal cell carcinoma and the only renal cell neoplasm to consistently harbor KRAS mutations.",
author = "Al-Obaidy, {Khaleel I.} and Eble, {John N.} and Mehdi Nassiri and Liang Cheng and Eldomery, {Mohammad K.} and Williamson, {Sean R.} and Sakr, {Wael A.} and Nilesh Gupta and Oudai Hassan and Idrees, {Muhammad T.} and Grignon, {David J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41379-019-0362-1",
language = "English (US)",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity

AU - Al-Obaidy, Khaleel I.

AU - Eble, John N.

AU - Nassiri, Mehdi

AU - Cheng, Liang

AU - Eldomery, Mohammad K.

AU - Williamson, Sean R.

AU - Sakr, Wael A.

AU - Gupta, Nilesh

AU - Hassan, Oudai

AU - Idrees, Muhammad T.

AU - Grignon, David J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We recently proposed that an epithelial renal tumor “papillary renal neoplasm with reverse polarity” represents a distinct entity. It constituted 4% of previously diagnosed papillary renal cell carcinoma at the participating institutions. Histologically, it is characterized by papillary or tubulopapillary architecture covered by a single layer of eosinophilic cells with finely granular cytoplasm and apically located nuclei. It is characteristically positive for GATA3 and L1CAM and lack vimentin and, to a lesser extent, α-methylacyl-CoA-racemase (AMACR/p504s) immunostaining. To investigate the molecular pathogenesis of these tumors, we performed targeted next-generation sequencing on ten previously reported papillary renal neoplasms with reverse polarity, followed by a targeted polymerase chain reaction analysis for KRAS mutations in a control series of 30 type 1 and 2 papillary renal cell carcinomas. KRAS missense mutations were identified in eight of ten papillary renal neoplasms with reverse polarity. These mutations were clustered in exon 2—codon 12: c.35 G > T (n = 6) or c.34 G > C (n = 2) resulting in p.Gly12Val and p.Gly12Arg alterations, respectively. One of the wild-type tumors had BRAF c.1798_1799delGTinsAG (p.Val600Arg) mutation. No KRAS mutations were identified in any of the 30 control tumors. In summary, this study supports our proposal that papillary renal neoplasm with reverse polarity is an entity distinct from papillary renal cell carcinoma and the only renal cell neoplasm to consistently harbor KRAS mutations.

AB - We recently proposed that an epithelial renal tumor “papillary renal neoplasm with reverse polarity” represents a distinct entity. It constituted 4% of previously diagnosed papillary renal cell carcinoma at the participating institutions. Histologically, it is characterized by papillary or tubulopapillary architecture covered by a single layer of eosinophilic cells with finely granular cytoplasm and apically located nuclei. It is characteristically positive for GATA3 and L1CAM and lack vimentin and, to a lesser extent, α-methylacyl-CoA-racemase (AMACR/p504s) immunostaining. To investigate the molecular pathogenesis of these tumors, we performed targeted next-generation sequencing on ten previously reported papillary renal neoplasms with reverse polarity, followed by a targeted polymerase chain reaction analysis for KRAS mutations in a control series of 30 type 1 and 2 papillary renal cell carcinomas. KRAS missense mutations were identified in eight of ten papillary renal neoplasms with reverse polarity. These mutations were clustered in exon 2—codon 12: c.35 G > T (n = 6) or c.34 G > C (n = 2) resulting in p.Gly12Val and p.Gly12Arg alterations, respectively. One of the wild-type tumors had BRAF c.1798_1799delGTinsAG (p.Val600Arg) mutation. No KRAS mutations were identified in any of the 30 control tumors. In summary, this study supports our proposal that papillary renal neoplasm with reverse polarity is an entity distinct from papillary renal cell carcinoma and the only renal cell neoplasm to consistently harbor KRAS mutations.

UR - http://www.scopus.com/inward/record.url?scp=85073921754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073921754&partnerID=8YFLogxK

U2 - 10.1038/s41379-019-0362-1

DO - 10.1038/s41379-019-0362-1

M3 - Article

C2 - 31534204

AN - SCOPUS:85073921754

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

ER -